ClinicalTrials.gg
CompletedNCT01757275Updated Mar 8, 2016Results posted

High Dose Esomeprazole Na for Prevention of Rebleeding After Successful Endoscopic Therapy of a Bleeding Peptic Ulcer

A Phase 3 interventional study of Esomeprazole Na and Cimetidine in Bleeding Peptic Ulcer, sponsored by AstraZeneca. Completed at 12 sites in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2016-03-08.

Sponsored by AstraZeneca · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
239
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Peptic Ulcer Hemorrhage with a site in China — 1 open to participants now, 1 under way, none of them phase 3. Peptic Ulcer Hemorrhage · China.

Started
2013
the only one that year
Phase 3
3 of 12
none open now
Registered
10th of 12
by date
Lead sponsor
2 of 12
AstraZeneca

Among the 12 studies in Peptic Ulcer Hemorrhage with a site in China, this one is the only one that started in 2013, is one of 3 in phase 3, and was the 10th registered.

Peptic Ulcer Hemorrhage

55 studies on the registry are indexed under Peptic Ulcer Hemorrhage; 6 are open to participants now.

Browse Peptic Ulcer Hemorrhage studies →

Open to participants now

1 of the 12 studies in Peptic Ulcer Hemorrhage with a site in China is open now. Recruiting first, the newest first:

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 2 Peptic Ulcer Hemorrhage studies recruiting now, 2 set no upper age limit and none stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Peptic Ulcer Hemorrhage with a site in China, or all of them as a file.
02

Study summary

To describe the rate of clinically significant rebleeding during 72 hours continuous i.v. infusion of high dose esomeprazole Na in patients in China with primary successful endoscopic haemostatic therapy of a bleeding peptic ulcer, with cimetidine i.v. in

Read the detailed description

A multi-center, randomised, double-blind, parallel-group phase III study to assess high dose esomeprazole Na i.v. treatment (bolus infusion of 80 mg followed by a continuous infusion of 8 mg per hour administered for 72 hours) for prevention of rebleeding

03

Conditions studied

  • Bleeding Peptic Ulcer

Keywords

  • peptic ulcer bleeding
  • prevention of rebleeding
  • successful endoscopic haemostatic therapy
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of prior to any study specific procedures.
  • Female or male aged =18 years and =70 years.
  • Acute upper gastrointestinal bleeding (haematemesis, melaena or haematochezia) or such signs within the last 24 hours as judged by the investigator.
  • One endoscopically confirmed bleeding gastric or duodenal peptic ulcer, at least 5 mm in diameter, classified as Forrest Ia, Ib, IIa, or IIb. Photo documentation of the source of bleeding should be provided.
  • Successful haemostasis (which is considered to have been established if bleeding has stopped and, if applicable, formerly bleeding vessels are flattened or cavitated) achieved by endoscopic treatment and confirmed by site staff.

Exclusion criteria

Exclusion Criteria:

  • Endoscopic suspicion of gastric or juxta pyloric stenosis as judged by the investigator.
  • Sign of multi PUB or concomitant other gastro bleeding from esophageal varices, reflux esophagitis, gastritis, Mallory Weiss rifts, ulcus simplex, Dieulafoy's lesion, colon, small bowel, or ulcer distal to the stom in Billroth-resected patients.
  • Need for treatment during the first 7 days of the study with NSAIDs, Cyclooxygenase-2 (COX-2) inhibitors, acetyl salicylic acid (ASA) (including low dose) or clopidogrel.
  • Planned treatment with: warfarin (including other vitamin K antagonists), cisapride, phenytoin, atazanavir, nelfinavir, digoxin, methotrexate, clopidogrel, tacrolimus, theophylline, lidocaine, nifedipine.
  • Chemotherapy or radiation therapies within 2 weeks prior to randomisation or planned during the course of the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
239 participants (actual)

Study arms

  • Experimental
    Esomeprazole

    Drug: Esomeprazole Na · Drug: Esomeprazole Mg

  • Active comparator
    Cimetidine

    Drug: Cimetidine

Interventions

  • Given as 80mg bolus infusion during 30 min and then 8mg/h constant infusion during 71.5 hous

    Also known as: Nexium

  • Given as 200mg bolus infusion during 30 min and then 60mg/h constant infusion during 71.5 hours

  • 40 mg tablet once daily for 27 days

    Also known as: Nexium

06

What researchers measure

Primary outcomes

  1. Rate of Clinically Significant Rebleeding Within 72 Hours

    Diagnostic criteria for clinically significant rebleeding based on either A, B or C: A) Endoscopy - initiated by clinical signs of bleeding defined as one of B1 or B2 or B3 and endoscopic verification, ie one of A1 or A2. A1: Blood in stomach (this criteria cannot be used during the first 6 hours after primary endoscopic haemostasis). A2: A verified active bleeding from a peptic ulcer (Forrest Ia, Ib). B) A true clinically based definition, at least two of B1 and/or B2 and/or B3. B1: Vomiting of fresh blood or fresh blood in a gastric tube or haematochezia or melaena after a normal stool. B2: Decrease in Hb \>20g/L (or Hct \>6%) during 24 hours or an increase in Hb \<10g/L (or Hct \<3%) despite ≥2 units of blood has been transfused during 24hours. B3: Unstable circulation systolic blood pressure ≤ 90 mmHg or pulse ≥110/min (after have had a stable circulation). C) Haematemesis. Vomiting significant amounts (\>200 ml) of fresh blood as estimated by the investigator.

    Time frame: 72 hours

Secondary outcomes

  1. Rate of Clinically Significant Rebleeding During 7 Days

    Diagnostic criteria for clinically significant rebleeding based on either A, B or C: A) Endoscopy - initiated by clinical signs of bleeding defined as one of B1 or B2 or B3 and endoscopic verification, ie one of A1 or A2. A1: Blood in stomach (this criteria cannot be used during the first 6 hours after primary endoscopic haemostasis). A2: A verified active bleeding from a peptic ulcer (Forrest Ia, Ib). B) A true clinically based definition, at least two of B1 and/or B2 and/or B3. B1: Vomiting of fresh blood or fresh blood in a gastric tube or haematochezia or melaena after a normal stool. B2: Decrease in Hb \>20g/L (or Hct \>6%) during 24 hours or an increase in Hb \<10g/L (or Hct \<3%) despite ≥2 units of blood has been transfused during 24hours. B3: Unstable circulation systolic blood pressure ≤ 90 mmHg or pulse ≥110/min (after have had a stable circulation). C) Haematemesis. Vomiting significant amounts (\>200 ml) of fresh blood as estimated by the investigator.

    Time frame: 7 days

  2. Rate of Clinically Significant Rebleeding During 30 Days

    Diagnostic criteria for clinically significant rebleeding based on either A, B or C: A) Endoscopy - initiated by clinical signs of bleeding defined as one of B1 or B2 or B3 and endoscopic verification, ie one of A1 or A2. A1: Blood in stomach (this criteria cannot be used during the first 6 hours after primary endoscopic haemostasis). A2: A verified active bleeding from a peptic ulcer (Forrest Ia, Ib). B) A true clinically based definition, at least two of B1 and/or B2 and/or B3. B1: Vomiting of fresh blood or fresh blood in a gastric tube or haematochezia or melaena after a normal stool. B2: Decrease in Hb \>20g/L (or Hct \>6%) during 24 hours or an increase in Hb \<10g/L (or Hct \<3%) despite ≥2 units of blood has been transfused during 24hours. B3: Unstable circulation systolic blood pressure ≤ 90 mmHg or pulse ≥110/min (after have had a stable circulation). C) Haematemesis. Vomiting significant amounts (\>200 ml) of fresh blood as estimated by the investigator.

    Time frame: 30 days

  3. Number of Patients With Endoscopic Re-treatment Within 72 Hours

    Time frame: 72 hours

  4. Number of Patients With Endoscopic Re-treatment Within 30 Days

    Time frame: 30 days

  5. Number of Patients With Surgery Due to Rebleeding Within 72 Hours

    Time frame: within 72 hours

  6. Number of Patients With Surgery Due to Rebleeding Within 30 Days

    Time frame: within 30 days

  7. Number of Blood Units Transfused Within 72 Hours

    Time frame: within 72 hours

  8. Number of Blood Units Transfused Within 30 Days

    Time frame: within 30 days

07

Results

Posted Mar 8, 2016
Limitations and caveats
No hypothesis testing was performed in this study and, as such, no formal statistical comparisons were made. Two patients who were initially randomised to receive cimetidine treatment actually received esomeprazole treatment.

Participant flow

Overall, 239 patients were enrolled from 19 centres in China. The first patient entered the study on 26 February 2013 and the last patient completed the study on 30 December 2014. Of the 239 patients enrolled into the study, 222 (92.9%) patients were randomised to treatment.

Participant flow — Overall Study
MilestoneEsomeprazoleCimetidine
Started111111
Completed10298
Not completed913
Withdrew: Lost to follow-up12
Withdrew: Adverse event33
Withdrew: Withdrawal by subject24
Withdrew: Not treated34

Outcome measures

PrimaryRate of Clinically Significant Rebleeding Within 72 Hours

Diagnostic criteria for clinically significant rebleeding based on either A, B or C: A) Endoscopy - initiated by clinical signs of bleeding defined as one of B1 or B2 or B3 and endoscopic verification, ie one of A1 or A2. A1: Blood in stomach (this criteria cannot be used during the first 6 hours after primary endoscopic haemostasis). A2: A verified active bleeding from a peptic ulcer (Forrest Ia, Ib). B) A true clinically based definition, at least two of B1 and/or B2 and/or B3. B1: Vomiting of fresh blood or fresh blood in a gastric tube or haematochezia or melaena after a normal stool. B2: Decrease in Hb \>20g/L (or Hct \>6%) during 24 hours or an increase in Hb \<10g/L (or Hct \<3%) despite ≥2 units of blood has been transfused during 24hours. B3: Unstable circulation systolic blood pressure ≤ 90 mmHg or pulse ≥110/min (after have had a stable circulation). C) Haematemesis. Vomiting significant amounts (\>200 ml) of fresh blood as estimated by the investigator.

Time frame:
72 hours
Reported as:
Number · participants
Rate of Clinically Significant Rebleeding Within 72 Hours
participantsEsomeprazoleCimetidine
No rebleeding107101
Rebleeding16
SecondaryRate of Clinically Significant Rebleeding During 7 Days

Diagnostic criteria for clinically significant rebleeding based on either A, B or C: A) Endoscopy - initiated by clinical signs of bleeding defined as one of B1 or B2 or B3 and endoscopic verification, ie one of A1 or A2. A1: Blood in stomach (this criteria cannot be used during the first 6 hours after primary endoscopic haemostasis). A2: A verified active bleeding from a peptic ulcer (Forrest Ia, Ib). B) A true clinically based definition, at least two of B1 and/or B2 and/or B3. B1: Vomiting of fresh blood or fresh blood in a gastric tube or haematochezia or melaena after a normal stool. B2: Decrease in Hb \>20g/L (or Hct \>6%) during 24 hours or an increase in Hb \<10g/L (or Hct \<3%) despite ≥2 units of blood has been transfused during 24hours. B3: Unstable circulation systolic blood pressure ≤ 90 mmHg or pulse ≥110/min (after have had a stable circulation). C) Haematemesis. Vomiting significant amounts (\>200 ml) of fresh blood as estimated by the investigator.

Time frame:
7 days
Reported as:
Number · participants
Rate of Clinically Significant Rebleeding During 7 Days
participantsEsomeprazoleCimetidine
No rebleeding105101
Rebleeding36
SecondaryRate of Clinically Significant Rebleeding During 30 Days

Diagnostic criteria for clinically significant rebleeding based on either A, B or C: A) Endoscopy - initiated by clinical signs of bleeding defined as one of B1 or B2 or B3 and endoscopic verification, ie one of A1 or A2. A1: Blood in stomach (this criteria cannot be used during the first 6 hours after primary endoscopic haemostasis). A2: A verified active bleeding from a peptic ulcer (Forrest Ia, Ib). B) A true clinically based definition, at least two of B1 and/or B2 and/or B3. B1: Vomiting of fresh blood or fresh blood in a gastric tube or haematochezia or melaena after a normal stool. B2: Decrease in Hb \>20g/L (or Hct \>6%) during 24 hours or an increase in Hb \<10g/L (or Hct \<3%) despite ≥2 units of blood has been transfused during 24hours. B3: Unstable circulation systolic blood pressure ≤ 90 mmHg or pulse ≥110/min (after have had a stable circulation). C) Haematemesis. Vomiting significant amounts (\>200 ml) of fresh blood as estimated by the investigator.

Time frame:
30 days
Reported as:
Number · participants
Rate of Clinically Significant Rebleeding During 30 Days
participantsEsomeprazoleCimetidine
No rebleeding105101
Rebleeding36
SecondaryNumber of Patients With Endoscopic Re-treatment Within 72 Hours
Time frame:
72 hours
Reported as:
Number · participants
Number of Patients With Endoscopic Re-treatment Within 72 Hours
participantsEsomeprazoleCimetidine
No re-treatment108106
Re-treatment01
SecondaryNumber of Patients With Endoscopic Re-treatment Within 30 Days
Time frame:
30 days
Reported as:
Number · participants
Number of Patients With Endoscopic Re-treatment Within 30 Days
participantsEsomeprazoleCimetidine
No re-treatment106106
Re-treatment21
SecondaryNumber of Patients With Surgery Due to Rebleeding Within 72 Hours
Time frame:
within 72 hours
Reported as:
Number · participants
Number of Patients With Surgery Due to Rebleeding Within 72 Hours
participantsEsomeprazoleCimetidine
No surgery108107
Surgery00
SecondaryNumber of Patients With Surgery Due to Rebleeding Within 30 Days
Time frame:
within 30 days
Reported as:
Number · participants
Number of Patients With Surgery Due to Rebleeding Within 30 Days
participantsEsomeprazoleCimetidine
No surgery108106
Surgery01
SecondaryNumber of Blood Units Transfused Within 72 Hours
Time frame:
within 72 hours
Reported as:
Number · blood units
Number of Blood Units Transfused Within 72 Hours
blood unitsEsomeprazoleCimetidine
Number of Blood Units Transfused Within 72 Hours1421
SecondaryNumber of Blood Units Transfused Within 30 Days
Time frame:
within 30 days
Reported as:
Number · blood units
Number of Blood Units Transfused Within 30 Days
blood unitsEsomeprazoleCimetidine
Number of Blood Units Transfused Within 30 Days1821

Adverse events

Collected over AEs will be collected from the time of the first administration of IP until the end of study, up to 35 days. SAEs will be collected from signed inform consent until the end of the study, up to 36 days.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Esomeprazole—5/110 (4.5%)22/110 (20%)
Cimetidine—5/105 (4.8%)20/105 (19%)
Most frequent serious events
Most frequent serious events
EventEsomeprazoleCimetidine
Duodenal ulcer haemorrhageGastrointestinal disorders2/1102/105
Gastrointestinal haemorrhageGastrointestinal disorders0/1101/105
BronchitisInfections and infestations0/1101/105
Persecutory delusionPsychiatric disorders0/1101/105
NephrolithiasisRenal and urinary disorders0/1101/105
Gastric ulcer haemorrhageGastrointestinal disorders1/1100/105
Blood fibrinogen decreasedInvestigations1/1100/105
Lung neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1100/105
Most frequent other events
Showing 10 of 51
Most frequent other events
EventEsomeprazoleCimetidine
Duodenal ulcer haemorrhageGastrointestinal disorders2/1102/105
MelaenaGastrointestinal disorders1/1102/105
PyrexiaGeneral disorders2/1102/105
CoughRespiratory, thoracic and mediastinal disorders2/1100/105
DiarrhoeaGastrointestinal disorders2/1101/105
BronchitisInfections and infestations0/1101/105
Upper respiratory tract infectionInfections and infestations0/1101/105
AnaemiaBlood and lymphatic system disorders0/1101/105
Haemorrhagic anaemiaBlood and lymphatic system disorders0/1101/105
Persecutory delusionPsychiatric disorders0/1101/105

Baseline characteristics

Among 222 randomised patients, 215 patients received iv treatment: 108 patients in the esomeprazole treatment group and 107 patients in the cimetidine treatment group.

Age, Continuous
Age, Continuous(years)EsomeprazoleCimetidineTotal
Age42.4 ± 12.7941.8 ± 12.9642.1 ± 12.85
Age, Customized
Age, Customized(participants)EsomeprazoleCimetidineTotal
<=65 years104103207
>65 years448
Sex: Female, Male
Sex: Female, Male(Participants)EsomeprazoleCimetidineTotal
Female252449
Male8383166
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)EsomeprazoleCimetidineTotal
Asian/Chinese108107215
Number of patients with one bleeding ulcer
Number of patients with one bleeding ulcer(participants)EsomeprazoleCimetidineTotal
Number108107215
Forrest class
Forrest class(participants)EsomeprazoleCimetidineTotal
Ia549
Ib5864122
IIa332457
IIb121527
Bleeding ulcer size
Bleeding ulcer size(mm)EsomeprazoleCimetidineTotal
Mean8.2 ± 4.88.1 ± 3.68.1 ± 4.3
Ulcer location
Ulcer location(participants)EsomeprazoleCimetidineTotal
Stomach17825
Duodenum8489173
Stomach and Duodenum71017

2 further baseline measures are reported on the registry.

08

Study locations

12 sites
  • Research Site
    Beijing, China
  • Research Site
    Changsha, China
  • Research Site
    Chongqing, China
  • Research Site
    Guangzhou, China
  • Research Site
    Ha'er bing, China
  • Research Site
    Hangzhou, China
  • Research Site
    Ji Nan, China
  • Research Site
    Nanchang, China
  • Research Site
    Nanjing, China
  • Research Site
    Shanghai, China
  • Research Site
    Wuhan, China
  • Research Site
    Xian, China
09

References and documents

Publications

  • Bai Y, Chen DF, Wang RQ, Chen YX, Shi RH, Tian DA, Chen H, Eklund S, Li ZS; Chinese Peptic Ulcer Bleeding Research Group. Intravenous Esomeprazole for Prevention of Peptic Ulcer Rebleeding: A Randomized Trial in Chinese Patients. Adv Ther. 2015 Nov;32(11):1160-76. doi: 10.1007/s12325-015-0265-6. Epub 2015 Nov 18. PubMed 26581750 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2013, a primary completion of Dec 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2016, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 21, 2012
First posted
Dec 28, 2012
Start
Feb 2013
Primary completionActual
Dec 2014
CompletionActual
Dec 2014
Results first posted
Mar 8, 2016
Last update
Mar 8, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 8, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01757275
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Dec 28, 2012
Start date
Feb 2013
Primary completion
Dec 2014
Completion
Dec 2014
Results posted
Mar 8, 2016
Last update
Mar 8, 2016

Study contacts

Tore Lind, MD
study director · AstraZeneca Molndal, Sweden
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Esomeprazole

Start the discussion